US Stock MarketDetailed Quotes

DNLI Denali Therapeutics

Watchlist
  • 24.475
  • -0.025-0.10%
Trading Nov 26 11:42 ET
3.52BMarket Cap-8867P/E (TTM)

About Denali Therapeutics Company

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Company Profile

SymbolDNLI
Company NameDenali Therapeutics
Listing DateDec 8, 2017
Issue Price18.00
Founded2013
CEODr. Ryan J. Watts, PhD
MarketNASDAQ
Employees445
Fiscal Year Ends12-31
Address161 Oyster Point Boulevard
CitySan Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-615-866-8548
Websitehttp://www.denalitherapeutics.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Ryan J. Watts, PhD
  • Director, President and Chief Executive Officer
  • 7.88M
  • Dr. Alexander O. Schuth, M.D.
  • Secretary, Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer
  • 4.17M
  • Dr. Carole Ho, M.D.
  • Chief Medical Officer and Head of Development
  • 4.17M
  • Dr. Vicki L. Sato, PhD
  • Chairman of the Board
  • 459.43K
  • Steve E. Krognes
  • Director
  • 419.43K
  • Nancy A. Thornberry
  • Independent Director
  • 434.43K
  • Dr. David P. Schenkein, M.D.
  • Independent Director
  • 439.43K
  • Erik Harris
  • Independent Director
  • 429.43K
  • Peter S. Klein
  • Independent Director
  • 439.43K
  • Dr. Marc Tessier-Lavigne, PhD
  • Independent Director
  • 431.93K
  • Jennifer E. Cook
  • Independent Director
  • 429.43K
  • Jay T. Flatley
  • Independent Director
  • 444.43K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data